Structural Basis of Membrane-induced Cardiotoxin A3 Oligomerization*

Farhad Forouhar {ddagger} §, Wei-Ning Huang § ¶, Jyung-Hurng Liu {ddagger} ||, Kun-Yi Chien ¶, Wen-guey Wu ¶ ** and Chwan-Deng Hsiao {ddagger} {ddagger}{ddagger}

From the {ddagger} Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan 115, Institute of Bioinformatics and Structural Biology, National Tsing Hua University, Hsinchu, Taiwan 300, || Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan 114, Republic of China

Received for publication, August 22, 2002 , and in revised form, March 21, 2003.
    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
Cobra cardiotoxins (CTXs) have previously been shown to induce membrane fusion of vesicles formed by phospholipids such as cardiolipin or sphingomyelin. CTX can also form a pore in membrane bilayers containing a anionic lipid such as phosphatidylserine or phosphatidylglycerol. Herein, we show that the interaction of CTX with negatively charged lipids causes CTX dimerization, an important intermediate for the eventual oligomerization of CTX during the CTX-induced fusion and pore formation process. The structural basis of the lipid-induced oligomerization of CTX A3, a major CTX from Naja atra, is then illustrated by the crystal structure of CTX A3 in complex with SDS; SDS likely mimics anionic lipids of the membrane under micelle conditions at 1.9-Å resolution. The crystal packing reveals distinct SDS-free and SDS-rich regions; in the latter two types of interconnecting CTX A3 dimers, D1 and D2, and several SDS molecules can be identified to stabilize D1 and D2 by simultaneously interacting with residues at each dimer interface. When the three CTXSDS complexes in the asymmetric unit are overlaid, the orientation of CTX A3 monomers relative to the SDS molecules in the crystal is strikingly similar to that of the toxin with respect to model membranes as determined by NMR and Fourier transform infrared methods. These results not only illustrate how lipid-induced CTX dimer formation may be transformed into oligomers either as inverted micelles of fusion intermediates or as membrane pore of anionic lipid bilayers but also underscore a potential role for SDS in x-ray diffraction study of protein-membrane interactions in the future.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
Cobra cardiotoxins (CTXs)1 are amphiphilic three-finger (L1-L3) basic polypeptides that bind to cell membranes and depolarize cardiomyocytes to cause systolic heart arrest in the envenomed victim (1). CTX has also been named cytotoxin because it brings about membrane leakage against many cells including red blood cells and phospholipid membrane vesicles (2). This effect is due in part to the interaction of CTX with phospholipid bilayer. For instance, CTX-induced fusions of zwitterionic sphingomyelin vesicles and negatively charged cardiolipin model membranes have been reported, respectively, for CTXs from Taiwan cobra (Naja atra) and African cobra (Naja mossambica) venom (35). After a deep penetration of CTX II of N. mossambica into the acyl chain region of anionic lipid bilayers, an enhanced lipid mixing, as detected by fluorescence fusion essay and the appearance of fusion intermediate of well defined particles, presumably inverted micelles, as observed by freeze-fracture electron microscopy, have been shown to occur during the CTX-induced fusion process of cardiolipin vesicles (5). Apparently the reorganization of CTX-lipid complex plays an important role in the aforementioned CTX-induced membrane-related activity.

The lytic property of CTXs is attributed to the coexistence of an exposed hydrophobic patch and a cluster of basic residues forming a cationic zone (6). Based on the phosphatidylcholine (PC) membrane binding activities of CTXs, two distinct types of CTX, P-(Pro-30-containing) and S-(Ser-28-containing), have been identified (7, 8), of which the P-type CTX interacts more strongly than the S-type with membranes. The presence of the proline in P-type CTX imposes a {omega}-like conformation on L2 that tightly binds to a water molecule, which plays an important role in the CTX membrane binding activity (911). The presence of low sequence homology in L1 regions among CTXs (Fig. 1A) also hints at toxic specificity of these polypeptides. For instance, local conformational changes in L1 (Val-7–Pro-8 peptide bond) of cytotoxin II from Naja oxiana strongly reduce the binding of its minor (with cis-Pro-8) form as compared with the major (with trans-Pro-8) one to membranes (8, 12).



View larger version (24K):
[in this window]
[in a new window]
 
FIG. 1.
Sequence alignment of four CTXs and CTX A3-induced vesicle leakage of 6-CF. A, sequences of CTX A3, CTX A5 (accession code 1KXI [PDB] ), CTX (accession code 1CDT [PDB] ), and CTX {gamma} (accession code 1TGX [PDB] ) were aligned based on their structures. The labeled secondary structural elements derived from this work are shown above the alignment. B, the leakage of different lipid component vesicles is plotted as a function of time after adding toxin. Black line, CTX A3 within pure PS vesicle; red line, CTX A3 within 50% PS/PC vesicle; green line, CTX A3 within pure PC vesicle; blue line, CTX A5 within pure PS vesicle. Concentrations of CTXs and vesicle were 0.16 and 10 µM, respectively. C, initial rate of 6-CF leakage as function of CTX A3 concentration. Black square, pure PS; red circle, 50% PS/PC; green triangle, pure PC. The inset shows re-plotting of C with the squared x axis of toxin concentration.

 

CTX A3, a major component (>50% dried weight of all CTXs) of the venom of Taiwan cobra (2, 4), is a 60-residue P-type CTX (Fig. 1A). Like other CTXs, CTX A3 is a basic protein (pI = 9.38) that is capable of depolarizing cardiomyocytes and possesses lytic activity on many other cells. CTX A5, a minor component of the venom of the Taiwan cobra, is a 62-residue P-type CTX with strong lipid binding capability. Although it lacks cardiotoxicity, CTX A5 is also called cardiotoxin because its amino acid sequence is homologous to that of CTX A3 (4, 7). Fluorescence and NMR studies of CTXs in the presence of zwitterionic PC micelles indicate that L1-L3 become perturbed (7, 1214). Previous biophysical studies suggest that association of lipids, especially negatively charged ones such as phosphatidylglycerol (PG) and phosphatidic acid (PA), induce a significant increase in the {beta}-sheet content of CTX A3 (7, 13, 15, 16). To address these issues and to gain an insight into the mechanism of CTX-induced membrane leakage and fusion processes, we co-crystallized CTX A3 with SDS and determined its three-dimensional structure under micelle conditions. The results also provide the first high resolution molecular model of CTX-lipid complex to understand how lipid-induced CTX dimerization may contribute to the CTX oligomerization required for the formation of fusion intermediate and membrane pores in the previously reported CTX-induced membrane related activities.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
Materials and Purification—Rhodamine B isothiocyanate, fluorescently labeled dextrans FD-4 and FD-70, and fluorescein isothiocyanate-conjugated anti-rabbit IgG were purchased from Sigma. The phospholipids of PC, phosphatidylserine (PS), PG, and PA used in this study were obtained from Avanti Polar Lipids. Because these phospholipids contain palmitoyl-oleoyl fatty acyl chains, they are named POPC, POPS, POPG and POPA, respectively. CTX A3 and CTX A5 were purified by SP-Sephadex C-25 ion exchange chromatography followed by HPLC on a reverse phase C-18 column from crude venom of N. atra (Snake's education farms, Tainan, Taiwan) previously described (7).

Vesicle Preparation—Lipids were dried under vacuum overnight and then hydrated with 10 mM Tris buffer (pH 7.4) containing 150 mM NaCl. The suspension was frozen and thawed several times and was successively extruded through a polycarbonate filter with the pore size of 0.1 µm for obtaining homogeneous large unilamellar vesicles. For the pore size determination experiments, the buffer contained 2 mg/ml FD-4 and 4 mg/ml FD-70 or fluorescein isothiocyanate-conjugated IgG (17). Vesicles used in fluorescence-leakage experiments were formed in the presence of 10 mM Tris (pH 7.4), 75 mM NaCl, and 50 mM 6-carboxyfluorescein (6-CF). Sepharose CL-4B column was used to remove the residual fluorescent molecules outside of the vesicles, and the lipid concentration was determined by inorganic phosphate assay as described (18).

Chemical Modification of Methionine—Chemical modification of methionine residues was performed as described (19) with a slight modification. Briefly, 1 mM CTX A3 in 100 mM phosphate buffer (pH 2.5) containing 6 M guanidine-HCl was reacted with 10 mM iodoacetamide at room temperature. The reaction was monitored by analytical reverse phase HPLC followed by mass spectrometry. Two single- and one double-alkylated product could typically be obtained from this reaction. Each product was further characterized by mass spectrometry after CNBr cleavage and subsequent reduction of disulfide bonds. The identified various alkylated forms of CTXs were separated and purified by reverse phase HPLC.

Vesicle Leakage—Release of vesicle contents was detected by 6-CF fluorescence intensity. Although 6-CF displays low fluorescence intensity at high concentration, its intensity increases sharply at low concentrations. Vesicles containing 6-CF were incubated at a final volume of 1 ml of buffer in a 1 x 1-cm quartz cuvette. After the addition of CTX, the fluorescence intensity was monitored as a function of time for the CTX-induced vesicle leakage process. The 6-CF leakage was calculated using the following expression: leakage % = (FtFi)/(Ff Fi), where Fi is the initial fluorescence before adding proteins, Ft is the fluorescence reading at time t, and Ff is the final fluorescence determined by adding Triton 0.02% (4). The excited and emitted wavelengths were 480 and 520 nm, respectively.

Pore Size Determination—Fluorescein dextran/IgG-containing vesicle (1.2 mM and 50 µl) were treated either with Triton X-100, to determine the ratio of entrapped molecules, or with CTX A3, to examine differential molecule release. After 20 min, treated vesicle was applied to a 45 x 0.5-cm CL-4B column with an elution rate of 6 ml/h. The elution profile was determined by a Hitachi F1050 fluorescence spectrophotometer. Excitation and emission wavelengths were 490 and 530 nm, respectively. To estimate the fraction of released molecules, a best-fit Gaussian curve was used to determine the area of elution profiles. When the leakage fraction was relatively small and the best-fit Gaussian curve was difficult to obtain, the leakage fraction was determined by the peak height of elution profile. We assume the released fraction corresponds to Ii = Ioi(1 – exp(–Ri)) where Ii, Ioi, and Ri were the released amount, total amount, and intrinsic leakage factor of different marker i, respectively.

The selectivity was defined by the ratio of intrinsic leakage factor of co-encapsulated markers,

(Eq. 1)
where IFD and IOFD were estimated by elution profiles after treatment with different concentrations of CTX A3 and Triton 0.8%, respectively.

Crystallography—Crystals of CTX A3 in complex with SDS, belonging to P21212 space group with cell parameters of a = 74.90 Å, b = 76.20 Å, and c = 47.78 Å, were grown by the hanging drop method. One µl of the protein solution (10 mg/ml) was mixed with 1 µl of reservoir solution containing 100 mM sodium acetate (pH 4.6), 20% polyethylene glycol 400, 3% glycerol, and 24 mM SDS, which is well above its critical micelle concentration (7–10 mM). Crystals were flash-frozen in liquid nitrogen followed by cryo-data collection on an R-Axis IV imaging plate mounted on a Rigaku RU 300-rotating anode and subsequent data processing using DENZO (20). The structure was solved by the molecular replacement method using the crystal structure of CTX{gamma} (accession code 1TGX [PDB] ) as the search model. Using AMoRe (21), the initial solution containing three molecules in the asymmetric unit had an R-factor of 40%. After manually adjusting the position of L2, which significantly differed from that of the model (1TGX [PDB] ), as revealed by omit map of residues 26–34, and the addition of SDS and water molecules, the R-factor dropped to about 30%. Because the L2 of each molecule in the asymmetric unit adopts a different conformation, non-crystallographic symmetry was not imposed during refinement, for which CNS (22) and XtalView (23) were used. The current model with R-factor and R-free values of 22 and 27.75% from 30- to 1.9-Å resolution (Table I) was obtained after several iterative cycles of CNS refinement. PROCHECK (24) showed that 85.6% of the residues are in the most favored region with the remaining residues in the additional favored region. Coordinates have been deposited in the Protein Data Bank under accession code 1h0j.


View this table:
[in this window]
[in a new window]
 
TABLE I
Data collection and refinement statistics

 

Fluorescence Labeling—CTX (0.2 mM) was mixed with rhodamine B isothiocyanate (0.4 mM) in the presence of 100 mM phosphate buffer (pH 7.4) containing 6 M guanidine-HCl. The reaction mixture was incubated at room temperature for 12 h, and the resulting fluorescence-conjugated CTX was purified by HPLC. Single fluorescent probe-conjugated CTX was further identified using electrospray ionization mass spectrometry (Quatro Ultima, MicroMass). For characterization of the conjugated position on CTX, the sample was dissolved in 100% trifluoroacetic acid at 40 °C for 20 min to obtain conjugated amino acids of CTX and the subsequent molecular weight verified by mass spectrometry. Concentrations of fluorescence-labeled and unlabeled CTX were determined using extinction coefficients of {epsilon}558 = 105,000 M–1cm1 for rhodamine B-conjugated CTX A3, {epsilon}276 = 4185 M–1cm1 for CTX A3, and {epsilon}276 = 2813 M–1cm1 for CTX A5. For each experiment, only N-terminal fluorescence-conjugated CTXs were used.

Attenuated Total Reflection Fourier Transform Infrared (ATR FTIR) Experiments—ATR-FTIR spectra were collected at ambient temperature using a Bomem DA 8.3 FTIR system with a liquid nitrogen-cooled MCT detector. The internal reflection element was a zinc-selenium ATR plate (50 x 5 x 2 mm, Harrick, Ossining, NY) with an aperture angle of 45°. The ATR plates were washed with alcohol and deionized water and cleaned by plasma cleaner (Harrick) for the generation of clean and damp surface. CTX (20 µg), dissolved in D2O solution in the absence and presence of lipids (40 µg), was dried on the surface of the ATR plate and sealed in a D2O-saturated sample holder. The spectra (200 scans) were recorded at a spectral resolution of 2 cm1 with triangular apodization. Fourier self-deconvolution was calculated, with the optimal parameter of 141 cm for the half-width of undeconvolution band and 2.2 for the resolution enhancement factor K, as previously described (25).

Fluorescence Homotransfer—The steady-state fluorescence spectra for the determination of CTX oligomerization upon binding to anionic lipids were obtained on an SLM-4800 fluorescence spectrometer with excitation and emission wavelengths set at 550 and 580 nm, respectively. Fluorescence-labeled and unlabeled CTX were mixed in an appropriate molar ratio, as shown in Fig. 2, in the presence of 10 mM Tris buffer (pH 7.4) containing 150 mM NaCl. The final concentration of both proteins was maintained at 0.1 µM. Upon the addition of anionic lipids vesicles (30 µM) to fluorescence-labeled CTX, the fluorescence intensity spontaneously decreased as a result of the fluorescence energy homotransfer (self-quenching) during the oligomerization process. The effect of self-quenching became less if the intrinsic CTX was added to dilute the fluorescence-labeled CTX (26, 27). All experiments were performed at 25 °C.



View larger version (13K):
[in this window]
[in a new window]
 
FIG. 2.
Fluorescence spectra of a fixed and variable ratio of rhodamine B-conjugated CTX A3 and CTX A5 in presence of large unilamellar vesicles. A and B, fluorescence intensities of various molar ratio of rhodamine B-labeled CTX A3 and CTX A5 in the presence of large unilamellar vesicles are shown in panels A and B, respectively. Black dashed line, simulated curve of the monomers of CTX A3; dotted line, simulated curve of the CTX A3 dimer; solid line, simulated curve and line of the CTX A3 oligomer and CTX A5 dimer, respectively. Black square, PG vesicles; red circle, PS vesicles.

 


    RESULTS AND DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
Anionic Lipid-induced Oligomerization and Membrane Pore Formation of CTX A3—Although P-type CTXs are known to bind to micelles of zwitterionic lipid or membrane vesicles of sphingomyelin, their interaction with PC membranes at liquid crystalline state causes no detectable lytic effect (green line, Fig. 1B). However, introduction of acidic lipids such as PS into the model membrane leads to a significant CTX A3-induced leakage of 6-CF fluorescence probe (red and black lines, Fig. 1B). In contrast, despite stronger interaction of CTX A5 than CTX A3 with the PC membranes, there is no detectable CTX A5-induced leakage even in vesicles with 100% PS (blue line, Fig. 1B). That similar CTX-induced vesicle leakage can also be observed for vesicles formed by PG, PA, or sulfatide suggests electrostatic interactions between anionic lipids and cationic CTX A3 play a role in the CTX-induced leakage of negatively charged membranes. Concentration-dependent study of the effect of CTX A3-induced leakage further reveals a bimolecular interaction of CTX A3 might be involved since the initial leakage rate of the process depends on the square of the CTX A3 concentration (Fig. 1C and the inset).

CTX A3-induced membrane leakage may stem from formation of a toxin pore and/or its direct lytic action on membranes; both mechanisms require membrane-induced toxin oligomerization. To investigate whether the CTX A3 and CTX A5 molecules oligomerize in the presence of anionic lipid membranes, fluorescence energy transfer experiments were performed in the presence of rhodamine-labeled CTX A3 (Rh-CTX A3), or CTX A5 (Rh-CTX A5). If Rh-CTX is a monomer near the membrane surface, dilution of the Rh-CTX with the intrinsic CTX molecules could cause no change in the fluorescence intensity (black dashed line in Fig. 2). Conversely, if Rh-CTX exists as either dimer or oligomer upon dilution of Rh-CTX with intrinsic CTX, the efficiency of fluorescence energy transfer among Rh-CTXs would decrease. Theoretical consideration of the quantitative effect of fluorescence energy transfer suggests a linear decrease for the CTX dimer and an even faster decrease for the CTX oligomer (Fig. 2A). Quantitative analysis of the result indicates that although CTX A3 forms oligomer (>dimer) in the presence of negatively charged lipids (green line in Fig. 2A), CTX A5 forms only dimer (Fig. 2B). This in turn suggests an interactive relationship between oligomerization and membrane leakage in the case of CTX A3.

To see whether membrane pore formation of CTX A3 indeed occurs near the anionic lipid membrane surface, we ask whether the CTX-induced leakage of the co-entrapped fluorescence probe exhibits selectivity toward molecules with different sizes. Although Triton-treated PS vesicles allow the complete leakage of the fluorescently labeled dextran probe of both FD-70 (Mr = 50.7 kDa) and FD-4 (Mr = 4.4 kDa) (green line in Fig. 3A), CTX A3-treated PS vesicles retain more of FD-70. FD-70 has been suggested to be a prolate ellipsoid (28). Based on the short axis of dextran, it is estimated that the lower limit of the pore size is ~20 Å (17). The selectivity value of CTX-induced pore was determined to be ~1.8 ± 0.3, which was smaller than that of melittin-treated in POPC vesicles. This result implies that the size or lifetime of the CTX-induced pore is larger or longer than that of the melittin-induced pore. Because all co-entrapped IgG remained within the CTX A3-treated vesicles (Fig. 3B), the result further suggests an upper limit for the size of the pore is ~100 Å, which corresponds to the diameter of an IgG molecule (29). Based on the aforementioned result, we conclude that the anionic lipid may induce the oligomerization of CTX A3 near the membrane surface and formation of a pore with a size ranging between 20 and 100 Å. Because the interaction of CTX with other anionic lipid such as cardiolipin also induces the formation of well defined membrane particles, presumably inverted micelles, as its fusion intermediates, it is desirable to obtain a high resolution structure to understand the mechanism responsible for the CTX action on phospholipid membranes. We consequently co-crystallized CTX A3 with anionic lipid of SDS and determined its three-dimensional structure at 1.9-Å resolution.



View larger version (21K):
[in this window]
[in a new window]
 
FIG. 3.
Elution profiles for the treated pure PS vesicle with co-encapsulated different fluorescence makers. A, elution profile of FD-4- and FD-70-co-encapsulated vesicle (black line) treated by 20 µM CTX A3 (red line) and Triton 0.8% (green line). The selectivity was 1.8 ± 0.3 using previous equation. B, elution profile of FD-4 and fluorescein-conjugated IgG co-encapsulated vesicle (black line) treated by CTX A3 30 µM (red line) and Triton 0.8% (green line).

 

Overall Structure of CTX A3—There are three crystallographically unrelated CTX A3 molecules in an asymmetric unit; each molecule forms a dimer with its closest neighbor from an adjacent asymmetric unit. The crystal structure of CTX A3 contains five {beta}-sheets comprising residues 2–4 ({beta}1), 11–13 ({beta}2), 20–26 ({beta}3), 35–39 ({beta}4), and 49–54 ({beta}5). The three functional loops are formed by residues 4–11 (L1), 26–35 (L2), and 39–49 (L3) (Fig. 1A). The C{alpha} structural overlay of the three molecules in the asymmetric unit (Fig. 4A) reveals that the most significant structural variation between monomers occurs at the tip of L2. Two monomeric (blue and magenta in Fig. 4A) L2s adopt similar conformations, with each bound to an SDS head group, whereas the L2 of the third CTX A3 molecule (green in Fig. 4A) has a conformation that closely resembles that of the molecule in solution determined by 1H NMR (yellow in Fig. 4A) (11, 30). This suggests that L2 undergoes a local and specific conformational change in the presence of SDS.



View larger version (22K):
[in this window]
[in a new window]
 
FIG. 4.
Structural overlay of the NMR and crystal structures of CTX A3 and stereo view of the CTX A3-SDS complex. A, structural overlay of the three CTX A3 monomers (magenta, green, blue) in the asymmetric unit with that of 1H NMR one (yellow) (accession code 1I02 [PDB] ). DINO (www.dino3d.org.) was used for drawing Figs. 4, 5, 6, A–C, 8, and 9. B, stereo ribbon diagram of a CTX A3 monomer, 6 SDS, and 4 water molecules showing direct or water-mediated interactions of CTX A3 with the SDS molecules. The SDS molecules are represented as ball-and-stick models, and water molecules are depicted in blue. The side chains of Lys-5, Pro-30, Lys-31, and Arg-36 are shown as ball-and-stick models. The 2FoFc electron density map in light blue mesh was generated after omitting the six SDS molecules and contoured at 1{sigma}.

 



View larger version (23K):
[in this window]
[in a new window]
 
FIG. 5.
Orientation of CTX A3 relative to SDS and negatively charged monolayer. A, overlay of the three CTX A3 monomers and their interacting SDS molecules in the asymmetric unit. CTX A3 interacts with the head groups of the SDS molecules at an angle of ~45°. B, the orientation of CTX A3 with respect to the negatively charged monolayer is depicted in panel B. Lipid interface is on the x-y plane, and the N terminus of CTX A3 faces the bulk phase. The slightly curved CTX A3 molecule is shown to bind to the membrane surface with an angle of ~ 48o ± 20°, as measured between the plane of CTX A3 and that normal to the monolayer.

 


View larger version (36K):
[in this window]
[in a new window]
 
FIG. 6.
Ribbon diagram of D1, D2, and D2' in complex with SDS and schematic of SDS-interaction at the interfaces of D1 and D2. A, stereo view of the D1-SDS complex. B and C, stereo views of the D2-SDS and D2'-SDS complexes. D, schematic of the SDS molecules interacting with the residues of CTX A3 at the interfaced of D1 (molecules labeled A and B) and D2 (molecules labeled A and C). The SDS molecules and the toxin residues are labeled accordingly. Dotted and golden lines are depicted as hydrophilic and hydrophobic interactions. Water molecules are shown as cyan balls.

 


View larger version (36K):
[in this window]
[in a new window]
 
FIG. 8.
Two views of the packing of SDS molecules in the crystal suggest a structural model for the involvement of CTX dimer in the CTX-induced vesicle aggregation and fusion intermediate. A, view along the b axis of the crystal, revealing the arrangements of the SDS molecules in three layers. The schematic diagram is shown to suggest that the aggregation of two membranes may be promoted by the formation of D2' dimer. A ribbon diagram of the four interconnecting CTX A3 molecules, of which blue and green represent D2', green and magenta represent D1, and magenta and light blue represent D2, are also shown. The unit cell and its axes are shown with yellow lines. B, view is parallel to the a–c plane of the crystal, showing the packing of four quasi-micelles of the SDS molecules depicted as ball-and-stick models. Three molecules of CTX A3 forming a D2 (light blue and magenta) and a D1 (magenta and green) are represented as ribbon diagrams. A schematic diagram is shown to suggest that inverted micelles or the presumed fusion intermediates can be formed by the interaction of D2 dimer with neighboring SDS molecules.

 


View larger version (45K):
[in this window]
[in a new window]
 
FIG. 9.
Ribbon diagram of the CTX A3 tetramer with SDS and pore-like structure. A, ribbon representation of the CTX A3 tetramer in complex with SDS. Two dimers, D2 (magenta-cyan) and D2' (green-blue), are connected in D1 (green-magenta) conformation. B, oligomerization of various dimers may form pore-like structure found in the crystal. Membrane lipids are expected to surround the D2' dimer once it is transformed into D2 dimer via specific lipid interaction (Fig. 6B). MSMS (40) was used for drawing surface.

 
CTX A3 contains only two acidic residues, Asp-40 and Asp-57, of which the side chain of Asp-40 is exposed to the solvent, and the OD1 of Asp-57 hydrogen bond with the NH of Lys-2. The latter observation is consistent with fluorescence data generated from a study into the effect of the mutation of Asp-57 to Asn on the unfolding process of CTXs (31).

Interactions of a CTX A3 Monomer with SDS Molecules—In the current structure, 10 SDS molecules were found to interact with 3 CTX A3 monomers in the asymmetric unit. Although any of the positively charged amino acids distributed throughout the slightly curved surface of CTX A3 can potentially interact with the SDS sulfate head groups, those residing on or near the three loops are found to be involved in the CTX A3-SDS interactions (Figs. 4B and 5A). Interestingly, the toxin backbone of 2 amino acid triads, Lys-5-Leu-6–Val-7 and Thr-29–Pro-30–Lys-31, from the respective L1 and L2 are also important contributors in CTX A3-SDS interactions, as each adopts a conformation that wraps around the SDS sulfate moiety (see SDS 2 and 4 in Fig. 4B). Consistent with previous biochemical and NMR studies in aqueous solution, the mode of the CTX A3-SDS interaction observed in the crystal implies that the three loops, L1-L3, initiate the CTX A3-membrane interaction. However, the current structure provides a molecular model on how negatively charged lipids may interact with the positively charged amino acids flanking the three hydrophobic loops that enhance the CTX-membrane interactions.

Although all the three loops interact with SDS, they differ in the intensity of their interaction, with L2 providing the strongest interaction with SDS molecules and L3 the least. More importantly, the head groups of half of the total SDS population hydrogen bond with Lys-31 of L2 of the 3 CTX monomers, suggesting that Lys-31 is the most important residue for the toxin-membrane electrostatic interaction, even though it is not strictly conserved in all CTXs. In the absence of a recombinant CTX A3, it is difficult to verify whether Lys-31 has a critical role in the toxicity of CTX A3. Nevertheless, being the major component of the venom of the wild cobra implies that CTX A3 has a major role in the toxicity of the venom, thereby suggesting that Lys-31 may also be important for its specific activity.

Last, Pro-30, which is only present in P-type CTXs, enhances the CTX-membrane interaction (see below), with the Val-7–Pro-8 peptide bond of L1, similar to that of cytotoxin II of N. oxiana (12), having a trans conformation. Apart from polar interactions between CTX A3 and the SDS head groups, the hydrophobic residues of CTX A3 make extensive interactions with the acyl moieties of SDS molecules, as discussed below.

The most stable water molecule, WAT1, having the lowest B-factor (Fig. 4B), resides at the center of the {omega}-shaped tip of L2, where it hydrogen-bonds with the O of Thr-29 and Val-32 and the NH of Met-26. As shown previously by NMR studies and molecular dynamics studies, it plays a critical role in the stability of L2 (11). Several other stable water molecules (very low B-factors) can also be identified near the tip of three loops, most of which are involved in CTX A3-SDS interactions (Fig. 4B). Water, therefore, appears to have an important intermediary role in the CTX A3-membrane interactions (see below).

To gain an insight into the orientation on which CTX A3 initiates its interaction with the cell membrane, we overlaid the three CTX A3-SDS complexes in the asymmetric unit. This revealed that the toxin interacts with SDS in an edgewise manner (Fig. 5A). Remarkably, polarized ATR FTIR experiments of CTX A3 in the presence of the aligned negatively charged PG monolayer also indicate a similar toxin orientation (~48 ± 20°) relative to the model membrane (Fig. 5B). Because similar binding modes involving the three hydrophobic loops of CTX A3 have previously been suggested using solid state NMR (32) and solution NMR (14) studies of CTXs with zwitterionic PC membranes, our result implies that the initial peripheral binding mode of CTX A3 with negatively charged membranes probably remains similar with neutral phospholipid membranes. Interestingly, the 3 CTX A3 monomers in the asymmetric unit interact with 6, 7, and 7 SDS molecules, which is remarkably consistent with the result of the fluorescence studies (33), showing that every CTX molecule interacts with 7 singly negatively charge phospholipids. In summary, all the available spectroscopic data suggest that CTX A3, via its three loops, interacts initially with surfaces of both neutral- and negatively charged membranes in an edgewise manner. But what remains to be addressed is how such an interaction leads to the final formation of a toxin pore or inverted micelles fusion intermediates near the membrane surfaces.

Dimers—In the crystal, the CTX A3 molecules interact with one another and form two types of dimers, D1 and D2 (or D2'). D1 (Fig. 6A) is formed by interactions of residues residing on the three loops; it buries 105-Å2 hydrophilic and 890-Å2 hydrophobic interactions using a probe radius of 1.5 Å. By comparison, D2 (Fig. 6B) or D2' (Fig. 6C), which is situated in a different SDS environment than that of D1, buries 297- and 617-Å2 hydrophilic and hydrophobic interactions, respectively. The interface of D2 or D2' is mainly contributed by the residues forming {beta}5 (Figs. 1A, 6B, and 6C).

Because interfaces of biologically relevant dimers usually bury 1400 Å2 (34, 35), it is unlikely that D1 and D2 can form in solution, as evidenced by NMR studies showing the existence of only monomeric species (11, 30). Conversely, both dimers are likely to form when either SDS molecules or model membranes are present in the solution. As shown in Fig. 6D, six SDS molecules involving hydrophilic and hydrophobic interactions at the D1 interface bury another 1000-Å2 surface area. Similarly, the participation of 6 SDS molecules at the D2 interface, which contribute another 1000-Å2 surface area, results in the further stabilization of D2 (Figs. 6D). The interactions of the SDS molecules with the interfaces of D1 and D2 are reminiscent of those of detergents crystallized with membrane proteins such as bacteriorhodopsin (36), as the acyl groups of several of them reside in the grooves of the toxin dimers.

The next obvious issue is whether CTX A3 forms D1 and D2 dimers in model membranes. In the D1 dimer, the side chains of Met-24 and Met-26 of each monomer forming D1 are clustered in close proximity to each other (Figs. 6A). These residues have been implicated in CTX-membrane interactions (14) and cytotoxicity (19). The side chains of Met-26 and Met-24, respectively, bury ~50- and ~25 Å2 at the dimer interface, suggestive of their important role in the D1 formation. To test whether methionines are important for the membrane-active property of CTX A3, we performed fluorescence experiments to check the effect of chemical modification on CTX A3-induced leakage of 6-CF trapped in large unilamellar vesicles. Whereas the chemical modification of Met-24 with iodoacetamide caused a ~40% reduction in 6-CF leakage compared with wild type CTX A3, that of Met-26 reduced it by 80%. The subsequent modification of both Met-24 and Met-26 diminished it by ~95% (Fig. 7A). By contrast, CTX A5, which lacks methionine residues at the corresponding positions, did not cause any leakage (Fig. 7A).



View larger version (19K):
[in this window]
[in a new window]
 
FIG. 7.
Vesicle leakage and ATR FTIR study of CTX A3 and CTX A5. A, the leakage of PS vesicles is plotted as a function of time after the addition of each toxin. Black line, native CTX A3; blue line, Met-24 modified CTX A3; green line, Met-26 modified CTX A3; cyan line. Met-24 and Met-26 modified CTX A3; red line, CTX A5. Concentrations of CTXs and vesicle were 0.08 and 5 µM, respectively. B, Fourier self-deconvolution FTIR spectra (enhanced factor K = 2.2 and {sigma} = 141 cm) in the amide I' region of CTX A3 (black line) in the absence and presence of PG (red line) and PA (green line).

 

In contrast to D1, the D2 and D2' are formed by the two {beta}5 strands. To verify whether D2 (or D2') occurs in the presence of detergents or lipids, we thus performed FTIR experiments on CTX A3 in the presence of PG and PA vesicles. Consistent with previous FTIR studies (15), the {beta}-sheet content of CTX A3 was enhanced upon toxin interaction with negatively charged lipids (Fig. 7B). The increase in the {beta}-sheet content of CTX A3 is because of the alignment of {beta}5 of each interacting monomer forming D2 (Fig. 6B). Previously, this result was interpreted as a lipid-induced conformational change of the CTX A3 monomer (14, 15). However, there is no detectable change in the {beta}-sheet content of the CTX A3 monomer obtained from the solution NMR and the one crystallized in the presence of SDS (Fig. 4A). Moreover, CTXs are highly stable polypeptides, as they retain most of their biological activities after boiling (37). It is, therefore, implausible that CTX A3 could undergo a conformation change that could result in an enhancement of {beta}-sheet content. It is also unlikely for L2, which is the most flexible CTX loop, to cause an increase in {beta}-sheet content, since with the aid of WAT1 it retains its {omega}-shaped conformation (Fig. 4, A and B), both in the presence of the model membrane in the solution (14) and the SDS molecules in the crystal. The current crystal structure, therefore, provides an alternative explanation for the significant increase in the {beta}-sheet content (Fig. 7B) of the highly rigid CTX A3; that is, the formation of D2 by the parallel alignment of two {beta}5 strands. In contrast to CTX A3, there is no detectable increase in the {beta}-sheet content for CTX A5 (data not shown).

Interestingly, we have recently solved the crystal structure of CTX A5 in complex with SDS.2 In the crystal, the CTX A5 molecules form only one type of dimer that resembles the one crystallized in the absence of SDS (10), at the interface of which {beta}5 and L3 of each interacting monomer are involved in hydrophilic and hydrophobic interactions. Because the {beta}5 of each CTX A5 forming the dimer is not aligned parallel to each other, as seen in D2 of CTX A3, it provides further evidence that the detected enhancement of the {beta}-sheet content of CTX A3 is due to the formation of D2.

Crystal Packing—The packing of the toxin and SDS molecules in the crystal also provides an interesting clue as to how SDS molecules mediate strong toxin-toxin interactions resulting in oligomer formation. When the crystal is viewed along the b axis, the SDS molecules are arranged in 3 disordered membrane-like SDS layers that have a width of ~25 Å and are spaced by ~30 Å. The CTX D2' dimers appear to play a role in bridging each membrane-like SDS layer (Fig. 8A). In contrast, if the crystal is viewed parallel to the a-c plane, a quasi-micelle of SDS molecules is visualized at each corner of the unit cell, at the center of which a D2 dimer is formed (Fig. 8B). Within the SDS layers (Fig. 8B), the CTX A3 molecules form D1, D2, and two types of weak toxin-toxin interactions (data not shown), whereas between the SDS layers only D2' dimers are formed (Figs. 6C and 8A). This structural evidence strongly suggests that the SDS molecules caused the tight packing of the toxin molecules within the layers, because the packing of solely D2' dimers between the layers is loose and has a significantly higher level of solvent content as compared with the SDS-rich regions (Fig. 8A). More interestingly, as indicated in the schematic diagram of Fig. 8, the structure suggests how the formation of D2' dimer may promote the membrane aggregation.

Oligomer—The significance of D1 can now be understood not only in its L2 coupling of each interacting monomer but also in its mediation between two crystallographically independent D2s (D2 and D2') in the formation of the CTX A3 "tetramer" (Figs. 8A and 9A) in terms of CTX A3 oligomerization. This observation in the crystal is consistent with the biophysical data (Fig. 2A), indicating that CTX A3 forms an oligomer (>dimer) in the presence of negatively charged lipids. Alternatively, the interactions of the four CTX A3 molecules constituting a D1, D2, and D2' within and between SDS layers (Fig. 8A) may represent the building blocks for CTX A3 oligomerization and eventual transient pore formation of CTX A3. Interestingly, the crystal packing also shows the pore-like structure formed by D1, D2, and D2' (Fig. 9B). Due to the demonstrated interaction of anionic lipid with D1 and D2, the putative pore can be seated into lipid bilayer if D2' is further converted into D2 by binding to more SDS molecules.

A Model for the CTX A3-Membrane Interaction—Based on the existence of 3–4 interacting CTX A3 monomers in the crystal, we propose the following chain of events taking place when CTX A3 interacts with the cell membrane with anionic phospholipids. (a) For the CTX-induced aggregation and fusion of anionic lipid vesicles such as cardiolipin, the initial contact of the L1-L3 loops with the negatively charged head group followed by the D2' dimer formation induces aggregation of vesicles. After the formation of D2 dimer through the binding of additional lipids to D2' dimer, D2 dimer may rearrange to allow the formation of inverted micelles as fusion intermediate. (b) For the CTX-induced pore formation of anionic lipid membrane such as phosphatidylserine, the initial contact of the L1-L3 loops with the negatively charged head groups of the cell membrane facilitates the formation of D1 (Fig. 6A), leading to possible destabilization of the membrane. This process is further intensified by interactions of the hydrophobic residues, notably Leu-6 and Pro-8 from L1, Ala-28, Pro-30, and Val-32 from L2, and Leu-47 and Leu-48 from L3, with acyl moieties of the phospholipids (Fig. 6D). The four-methionine cluster (Met-24 and Met-26 from each monomer) in the internal groove of D1 helps to facilitate the toxin-membrane interaction. At this point, D2 together with D1 could lead to CTX A3 oligomerization and a pore formation (Fig. 9B). However, unlike pore structures observed by pore-forming toxins (38), the architecture of CTX A3 does not suggest that the toxin molecules can make up a stable one. Nonetheless, there is evidence of CTX A3-induced pore formation in negatively charged liposomes (this work) and in bullfrog atrial myocytes (39), which is nonspecific and reversible, lasting a few seconds.

In summary, our structural and biophysical data provide a mechanism for CTX A3 oligomerization via anionic lipid-induced dimer formation, which likely leads to the formation of a pore or inverted micelles, depending on the type of negatively charged phospholipid membranes used for the study. The approach also underscores the importance of the SDS-protein co-crystallization, from which the present information concerning CTX A3-membrane interaction has been elicited.


    FOOTNOTES
 
The atomic coordinates and structure factors (code 1h0j) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

* This work was supported by National Science Council Grants NSC-90-2311-B-001-029 (to C.-D. H.) and NSC-90-2113-M-007-065 (to W.-g. W.) and a grant from the Academia Sinica, Taiwan, Republic of China (to C.-D. H.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

§ These authors contributed equally to this work. Back

** To whom correspondence may be addressed. Tel.: 886-3-573-1040; Fax: 886-3-571-5934; E-mail: wgwu{at}life.nthu.edu.tw. {ddagger}{ddagger} To whom correspondence may be addressed. Tel.: 886-2-2788-2743; Fax: 886-2-2782-6085; E-mail: mbhsiao{at}ccvax.sinica.edu.tw.

1 The abbreviations used are: CTX, cardiotoxin; PC, phosphatidylcholine; PS, phosphatidylserine; PG, phosphatidylglycerol; PA, phosphatidic acid; ATR, attenuated total reflection; FTIR spectroscopy, Fourier transform infrared spectroscopy; Rh, rhodamine; HPLC, high performance liquid chromatography; 6-CF, 6-carboxyfluorescein; ATR, attenuated total reflection. Back

2 J.-H. Liu, K.-Y. Chien, W.-g. Wu, and C.-D. Hsiao, unpublished results. Back


    ACKNOWLEDGMENTS
 
We thank Drs. Sunney I. Chan and K. Deen of Academia Sinica for helpful suggestions.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 

  1. Housset, D., and Fontecilla-Camps, J. C. (1996) in Protein Toxin Structure (Parker, M. W., ed) pp. 271–290, Springer-Verlag, Berlin
  2. Dufton, M. J., and Hider, R. C. (1987) Pharmacol. Ther. 36, 1–40[CrossRef]
  3. Aripov, T. F., Gasanov, S. E., Salakhutdinov, B. A., Rozenshtein, I. A., and Kamaev, F. G. (1989) Gen. Physiol. Biophys. 8, 459–474[Medline] [Order article via Infotrieve]
  4. Chien, K.-Y., Huang, W. N., Jean, J.-H., and Wu, W. (1991) J. Biol. Chem. 266, 3252–3259[Abstract/Free Full Text]
  5. Batenburg, A. M., Bougis, P. E., Rochat, H., Verkleij, A. J., and de Kruijff, B. (1985) Biochemstry 24, 7101–7110[Medline] [Order article via Infotrieve]
  6. Rees, B., and Bilwes, A. (1993) Chem. Res. Toxicol. 6, 285–405
  7. Chien, K. Y., Chiang, C. M., Hseu, Y. C., Vyas, A. A., Rule, G. S., and Wu, W. (1994) J. Biol. Chem. 269, 14473–14483[Abstract/Free Full Text]
  8. Efremov, R. G., Volynsky, P. E., Nolde, D. E., Dubovskii, P. V., and Arseniev, A. S. (2002) Biophys J. 83, 144–153[Abstract/Free Full Text]
  9. Bilwes, A., Rees, B., Moras, D., Menez, R., and Menez, A. (1994) J. Mol. Biol. 239, 122–136[CrossRef][Medline] [Order article via Infotrieve]
  10. Sun, Y. J., Wu, W. G., Chiang, C. M., Hsin, A. Y., and Hsiao, C. D. (1997) Biochemistry 36, 2403–2413[CrossRef][Medline] [Order article via Infotrieve]
  11. Sue, S. C., Jarrell, H. C., Brisson, J. R., and Wu, W. (2001) Biochemistry 40, 12782–12794[CrossRef][Medline] [Order article via Infotrieve]
  12. Dubovskii, P. V., Dementieva, D. V., Bocharov, E. V., Utkin, Y. N., and Arseniev, A. S. (2001) J. Mol. Biol. 305, 137–149[CrossRef][Medline] [Order article via Infotrieve]
  13. Dauplais, M., Neumann, J. M., Pinkasfeld, S., Menez, A., and Roumestand, C. (1995) Eur. J. Biochem. 230, 213–220[Abstract]
  14. Sue, S. C., Chien, K. Y., Huang, W. N., Abraham, J. K, Chen, K. M., and Wu, W. (2002) J. Biol. Chem. 277, 2666–2673[Abstract/Free Full Text]
  15. Surewicz, W. K., Stepanik, T. M., Szabo, A. G., and Mantsch, H. H. (1988) J. Biol. Chem. 263, 786–790[Abstract/Free Full Text]
  16. Chiang, C. M., Chang, S. L., Lin, H. J., and Wu, W. (1996) Biochemistry 35, 9177–9186[CrossRef][Medline] [Order article via Infotrieve]
  17. Ladokhin, A. S., Selsted, M. E., and White, S. H. (1997) Biophys J. 72, 1762–1766[Abstract]
  18. Lanzetta, P. A., Alvarez, L. J., and Reinach, P. S. (1979) Anal. Biochem. 100, 95–97[Medline] [Order article via Infotrieve]
  19. Carlsson, F. H. (1987) Int. J. Biochem. 19, 915–921[CrossRef][Medline] [Order article via Infotrieve]
  20. Otwinowski, Z., and Minor, W. (1997) Methods Enzymol. 276, 307–326
  21. Navaza, J. (1994) Acta Crystallogr. Sect. A 50, 157–163[CrossRef]
  22. Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Acta Crystallogr. Sect. D 54, 905–921[CrossRef][Medline] [Order article via Infotrieve]
  23. McRee, D. E. (1999) J. Struct. Biol. 125, 156–165[CrossRef][Medline] [Order article via Infotrieve]
  24. Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thorton, J. M. (1993) J. Appl. Crystallogr. 26, 283–291[CrossRef]
  25. Lin, Y. H., Huang, W. N., Lee, S. C., and Wu, W. (2000) Int. J. Biol. Macromol. 27, 171–176[CrossRef][Medline] [Order article via Infotrieve]
  26. Runnels, L. W., and Scarlata, S. F. (1995) Biophys. J. 69, 1569–1583[Abstract]
  27. Sharpe, J. C., and Landon, E. (1999) J. Membr. Biol. 171, 209–221[CrossRef][Medline] [Order article via Infotrieve]
  28. Bohrer, M. P., Deen, W. M., Robertson, C. R., Troy, J. L., and Brenner, B. M. (1997) J. Gen. Physiol. 74, 583–593
  29. Sarma, V. R., Silverton, E. W., Davies, D. R., and Terry, W. D. (1971) J. Biol. Chem. 246, 3753–3759[Abstract/Free Full Text]
  30. Bhaskaran, R., Huang, C. C., Chang, D. K., and Yu, C. (1994) J. Mol. Biol. 235, 1291–1301[CrossRef][Medline] [Order article via Infotrieve]
  31. Lo, C. C., Hsu, J. H., Shen, Y. C., Chiang, C. M., Wu, W., Fann, W., and Tsao, P. H. (1998) Biophys. J. 75, 2382–2388[Abstract/Free Full Text]
  32. Sue, S. C., Rajan, P. K., Chen, T. S., Hsieh, C. H., Wu, W. (1997) Biochemistry 36, 9826–9836[CrossRef][Medline] [Order article via Infotrieve]
  33. Dufourcq, J., and Faucon, J. F. (1978) Biochemistry 17, 1170–1176[Medline] [Order article via Infotrieve]
  34. Lo Conte, L., Chothia, C., and Janin, J. (1999) J. Mol. Biol. 285, 2177–2198[CrossRef][Medline] [Order article via Infotrieve]
  35. Jones, S., and Thornton, J. M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 13–20[Abstract/Free Full Text]
  36. Fyfe, P. K., McAuley, K. E, Roszak, A. W., Isaacs, N. W., Cogdell, R. J., and Jones, M. R. (2001) Trends Biochem. Sci. 26, 106–112[CrossRef][Medline] [Order article via Infotrieve]
  37. Klowden, M. J., Vitale, A. J., Trumble, M. J., Wesson, C. R., and Trumble, W. R. (1992) Toxicon 30, 295–301[CrossRef][Medline] [Order article via Infotrieve]
  38. Lesieur, C., Vecsey-Semjen, B., Abrami, L., Fivaz, M., and van der Goot, F. G. (1997) Mol. Memb. Biol. 14, 45–64[Medline] [Order article via Infotrieve]
  39. Wu, W. (1997) J. Toxicol. Toxin Rev. 16, 115–134
  40. Sanner, M. F., Spehner, J.-C., and Olson, A. J. (1996) Biopolymers 38, 305–320[CrossRef][Medline] [Order article via Infotrieve]